+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Alzheimer's Therapeutics Market Research Report by Diagnostics (Brain Imaging and CFS Test for Alzheimer's Disease), Drug Class, Distribution, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 234 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 5305530
UP TO OFF until Dec 31st 2022
The Global Alzheimer’s Therapeutics Market size was estimated at USD 5,223.86 million in 2021, USD 5,660.34 million in 2022, and is projected to grow at a CAGR 8.53% to reach USD 8,537.98 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Alzheimer’s Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Diagnostics, the market was studied across Brain Imaging and CFS Test for Alzheimer's Disease.
  • Based on Drug Class, the market was studied across Cholinesterase Inhibitors and NMDA [N-methyl-D-aspartate] Receptor Antagonist.
  • Based on Distribution, the market was studied across Online Pharmacies and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Alzheimer’s Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Alzheimer’s Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Alzheimer’s Therapeutics Market, including AbbVie, Alector, Altoida AG, Aphios Corporation, Applied BioMath, LLC, Asklepios BioPharmaceutical, Inc., Codiak Biosciences, Cortexyme, D&D Pharmatech, Denali Therapeutics, Genentech, Ionis Pharmaceuticals Inc, Verge Genomics, Voyager Therapeutics, vTv Therapeutics, and Wren Therapeutics.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Alzheimer’s Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Alzheimer’s Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Alzheimer’s Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Alzheimer’s Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Alzheimer’s Therapeutics Market?
6. What is the market share of the leading vendors in the Global Alzheimer’s Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Alzheimer’s Therapeutics Market?
Frequently Asked Questions about the Global Alzheimer’s Therapeutics Market

What is the estimated value of the Global Alzheimer’s Therapeutics Market?

The Global Alzheimer’s Therapeutics Market was estimated to be valued at $5223.86 Million in 2021.

What is the growth rate of the Global Alzheimer’s Therapeutics Market?

The growth rate of the Global Alzheimer’s Therapeutics Market is 8.5%, with an estimated value of $8537.98 Million by 2027.

What is the forecasted size of the Global Alzheimer’s Therapeutics Market?

The Global Alzheimer’s Therapeutics Market is estimated to be worth $8537.98 Million by 2027.

Who are the key companies in the Global Alzheimer’s Therapeutics Market?

Key companies in the Global Alzheimer’s Therapeutics Market include AbbVie, Alector, Altoida AG, Aphios Corporation, Applied BioMath, LLC, Asklepios BioPharmaceutical, Inc., Codiak Biosciences, Cortexyme and Denali Therapeutics.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of Alzheimer’s coupled with better healthcare facilities
5.1.1.2. Development and availability of pipeline drugs
5.1.1.3. Growing technologies for detection by early diagnosis
5.1.2. Restraints
5.1.2.1. Capital intensive treatment for Alzheimer’s
5.1.2.2. Increasing chances in failure of late-state drugs
5.1.3. Opportunities
5.1.3.1. Intense research and development with the inclusion of cloud-based cognitive systems and artificial intelligence
5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
5.1.4. Challenges
5.1.4.1. Stringent drug approval process
5.2. Cumulative Impact of COVID-19
6. Alzheimer’s Therapeutics Market, by Diagnostics
6.1. Introduction
6.2. Brain Imaging
6.3. CFS Test for Alzheimer's Disease
7. Alzheimer’s Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Cholinesterase Inhibitors
7.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist
8. Alzheimer’s Therapeutics Market, by Distribution
8.1. Introduction
8.2. Online Pharmacies
8.3. Retail Pharmacies
9. Americas Alzheimer’s Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Alzheimer’s Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Alzheimer’s Therapeutics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie
13.2. Alector
13.3. Altoida AG
13.4. Aphios Corporation
13.5. Applied BioMath, LLC
13.6. Asklepios BioPharmaceutical, Inc.
13.7. Codiak Biosciences
13.8. Cortexyme
13.9. D&D Pharmatech
13.10. Denali Therapeutics
13.11. Genentech
13.12. Ionis Pharmaceuticals Inc
13.13. Verge Genomics
13.14. Voyager Therapeutics
13.15. vTv Therapeutics
13.16. Wren Therapeutics
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET DYNAMICS
FIGURE 8. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2021 VS 2027 (%)
FIGURE 9. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2027
FIGURE 11. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 16. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 18. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (%)
FIGURE 23. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2021 VS 2027 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2027
FIGURE 25. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 26. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 28. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 29. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 31. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2027
FIGURE 33. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 39. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2027
FIGURE 41. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 43. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2027
FIGURE 45. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2027
FIGURE 60. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 63. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 64. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 65. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 67. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 68. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 69. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 72. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 73. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ALZHEIMER’S THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 17. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 18. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 20. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 22. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2019-2027 (USD MILLION)
TABLE 23. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY STATE, 2019-2027 (USD MILLION)
TABLE 25. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 27. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 28. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 29. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 31. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 33. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 34. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 36. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 38. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 39. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 41. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 42. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 43. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 44. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 45. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 46. ARGENTINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 47. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 48. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 49. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 50. BRAZIL ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 51. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 52. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 53. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 54. CANADA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 55. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 56. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 57. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 58. MEXICO ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 59. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 61. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 62. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 63. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 64. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 66. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 67. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 68. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 69. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 70. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 71. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 72. AUSTRALIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 73. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 74. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 75. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 76. CHINA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 77. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 79. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 80. INDIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 81. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 82. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 83. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 84. INDONESIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 85. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 87. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 88. JAPAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 89. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 90. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 91. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 92. MALAYSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 93. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 94. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 95. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 96. PHILIPPINES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 97. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 98. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 99. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 100. SINGAPORE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 101. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 102. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 103. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 104. SOUTH KOREA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 105. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 106. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 107. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 108. TAIWAN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 109. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 110. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 111. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 112. THAILAND ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 118. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 119. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 120. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 121. FRANCE ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 122. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 123. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 124. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 125. GERMANY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 126. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 127. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 128. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 129. ITALY ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 130. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 131. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 132. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 133. NETHERLANDS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 134. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 135. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 136. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 137. QATAR ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 138. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 139. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 140. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 141. RUSSIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 142. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 143. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 144. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 145. SAUDI ARABIA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 146. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 147. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 148. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 149. SOUTH AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 150. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 151. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 152. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 153. SPAIN ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 158. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 159. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2019-2027 (USD MILLION)
TABLE 160. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 161. UNITED KINGDOM ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2019-2027 (USD MILLION)
TABLE 162. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 163. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 164. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 165. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET RANKING
TABLE 166. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 167. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 168. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 169. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 170. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 171. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 172. GLOBAL ALZHEIMER’S THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie
  • Alector
  • Altoida AG
  • Aphios Corporation
  • Applied BioMath, LLC
  • Asklepios BioPharmaceutical, Inc.
  • Codiak Biosciences
  • Cortexyme
  • D&D Pharmatech
  • Denali Therapeutics
  • Genentech
  • Ionis Pharmaceuticals Inc
  • Verge Genomics
  • Voyager Therapeutics
  • vTv Therapeutics
  • Wren Therapeutics

Methodology

Loading
LOADING...